Quantcast

Industry news that matters to you.  Learn more

Cincinnati Children’s Issued Patent Covering Individualized Medication Dosing Technology Being Commercialized by Assurex Health

Cincinnati Children’s Hospital Medical Center (CCHMC) and Assurex Health recently announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,589,175 encompassing the “Optimization and Individualization of Medication Selection and Dosing” by Cincinnati Children’s inventors Drs. Tracy A. Glauser, Richard J. Wenstrup*, Alexander A. Vinks, and John P. Pestian. The CCHMC patent covers methods for optimizing dosing regimens for medications utilizing population models, genotype, and clinical information to treat patients with neuropsychiatric and other disorders.

Genomind Announces New Portal at NEI Global Psychopharmacology Congress

Genomind, a personalized medicine company for neuropsychiatry, is excited to announce its new clinician online portal at the Neuroscience Education Institute (NEI) Global Psychopharmacology Congress in San Diego. Genomind will host a Product Theater at the Congress on Saturday, October 20, 2012 at 7 am, where co-founder and Chief Scientific Officer Dr. Jay Lombard will discuss the Company’s Genecept Assay, introduce attendees to the new system, and showcase the convenient features for clinicians.

The portal is a secure, convenient way for clinicians to easily access their patients’ test results from the Genecept Assay. The Assay is Genomind’s comprehensive, saliva-based test, which looks at genes and biomarkers that may affect the type of medication or treatment a clinician would prescribe to patients suffering from difficult-to-treat psychiatric disorders. The secure site allows clinicians to review and download comprehensive reports via login credentials any time or place, giving flexibility to their busy schedules. All results will be available electronically and can be downloaded directly from the portal. The portal also allows easy access to peer-reviewed study data related to genes in the panel.

The portal is also the home of Genomind’s innovative Open Label Study, which measures the real world use and impact of the Genecept Assay on patient treatment and outcomes. The study has a unique design to enable timely, efficient reporting online for clinicians and patients.

The portal will be accessible on the Genomind website homepage or via email alerts sent to clinicians once their patients’ test results are live and available.

The Neuroscience Education Institute Annual Conference runs from October 18-21, 2012, at the Manchester Grand Hyatt in San Diego. In addition to the Product Theater, Genomind will be available on the main show floor at Booth 115 to share more information about the portal, the Genecept Assay, and their dedication to harnessing the latest research to better treat patients.

Source: Genomind

Enhanced Biomarker Test Aids Clinicians With Difficult to Treat Psychiatric Disorders

Genomind recently announced enhancements to its Genecept™ Assay, a proprietary biomarker test and analytic report, which helps inform treatment options in neuropsychiatry. The enhancements include adding three new genes to its panel, a redesigned report, and an upgraded technical platform.

Researchers Find Possible Biomarker to Identify Seizure-Related Stress

New research from Rhode Island Hospital found that reduced levels of brain-derived neurotrophic factor (BDNF), a protein in the brain that encourages growth of neurons, may be a trait marker for individuals with psychogenic non-epileptic seizures (PNES) (seizures that are psychological in origin). The findings are published in the October 4, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.